Zaiding pharmaceutical appointed Dr Valeria Fantin as chief scientific officer

June 3, 2019 / AP / -- zaiding pharmaceutical announced on June 3 that Dr Valeria Fantin was appointed chief scientific officer of the company Dr Fantin will report directly to Dr Du Ying, founder and CEO of zaiding pharmaceutical She will work in San Francisco, the company's U.S headquarters, and be responsible for the global internal R & D of zaiding pharmaceutical Before joining zaiding, Dr Fantin held the post of chief scientific officer in oricpharmaceuticals Dr Du Ying, founder and CEO of zaiding pharmaceutical, said: "Valeria is an outstanding R & D leader with more than 20 years of experience in tumor drug research and rich expertise in drug research and development Zaiding pharmaceutical is fully promoting the internal R & D pipeline, and hopes to submit one or two new drug clinical trial applications (ind) every year from 2020 Valeria is undoubtedly the most qualified person to lead this goal and will further help us strengthen our internal R & D strength " Dr Fantin said: "I'm very excited to join zaiding pharmaceutical and help the company further strengthen its pharmaceutical R & D strength and expand its internal R & D pipeline I hope that my experience as a cancer researcher and drug R & D director can help zaiding achieve the vision of creating a rich pipeline of innovative drug R & D " As a senior industry leader, Dr Fantin has more than 20 years of industry experience in biological exploration research and tumor drug development During oriC, Dr Fantin was responsible for the establishment of the company's research team and the establishment of the product pipeline for the drug-resistant mechanism of tumor treatment, including the introduction of the GR antagonist oric-101 from the laboratory stage to the clinical stage Prior to joining oriC, Dr Fantin was vice president of cancer cell biology of Pfizer He was responsible for promoting small molecule and biomacromolecule drugs from target validation stage to clinical phase II concept validation stage, including research on signal pathway, metabolism, epigenetics and immunotumor During Pfizer, Dr Fantin participated in the development of the innovative drug piperacillin (aiboxin ®), the ALK inhibitor loratinib (lorbrena ®), which can treat brain metastasis, and the discovery of several other currently ongoing Ph1 / pH2 compounds Prior to that, Dr Fantin also held a management position in Agios pharmaceuticals, creating and promoting research on new targets of tumor metabolism in the company, and bringing them into drug discovery stage She led the research of Agios' iconic isocitrate dehydrogenase project, which provides a scientific basis for the recently approved idh2 and IDH1 inhibitors, enasidenib (idhifa ®) and ivosidenib (tibsovo ®) Earlier, she also worked as a researcher in Merck Research Laboratory Her research direction is epigenetics and kinase drug discovery, and she has made contributions to the research and development of the innovative HDAC inhibitor vorinolta (Zolinza ®) Dr Fantin holds a Ph.D in molecular and cellular biology from Dartmouth School of medicine, and has completed postdoctoral research on cancer metabolism and signal transduction at Harvard Medical School and Howard Hughes Institute of medicine About zaiding pharmaceutical zaiding Pharmaceutical (NASDAQ: zlab) is an innovative biopharmaceutical company based in China and operated globally It is committed to providing innovative drugs for cancer, autoimmune and infectious diseases patients in China and around the world The company's experienced team has established strategic cooperation with the world's leading biopharmaceutical companies to create a series of candidate innovative drugs to meet the rapid growth of China's pharmaceutical market and unmet global medical needs The vision of zaiding pharmaceutical is to become a comprehensive and innovative biopharmaceutical company, to develop, produce and sell products of independent research and development and partners, and to work hard for the promotion of human health and well-being all over the world Source: zaiding medicine